Radiotherapy for management of basal and squamous cell carcinoma

Ström, T.; Harrison, Louis B.

doi:10.1016/j.currproblcancer.2015.07.003

Cited by 12 publications

(8 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another reason to choose radiation over surgery could also be for recurrent tumors that have shown to be more aggressive and become progressively more difficult to treat with surgery. It might also be a suitable therapy option for patients who have contraindications for anesthesia and therefore cannot have an extensive surgical intervention as well as the desire for curative BCC treatment with organ preservation, bone infiltration or with a possible protection of the patient's physiognomy (38)(39)(40). Healing rates of the various forms of irradiation, fractional forms, conventional radiotherapy as well as brachytherapy, are comparable to conventional surgery.…”

Section: Radiotherapymentioning

confidence: 99%

Alternative treatment options for periocular basal cell carcinoma: a narrative review

Erikson¹,

Brosig²,

Zimbelmann³

et al. 2022

Front Oral Maxillofac Med

View full text Add to dashboard Cite

This literature review presents the latest developments as well as established procedures that offer alternative treatment approaches to basal cell carcinoma (BCC) when micrographically controlled surgical removal is not possible. Micrographically controlled surgical removal remains the gold standard in the treatment of BCC. When surgical removal is impossible, other procedures can be chosen. The alternative treatment options can be divided into three main groups: treatment options for locally advanced or metastasized BCC, topical approaches for small and superficial BCC and prophylactic measures.While radiotherapy and systemic therapy are suitable for locally advanced BCC that are discussed in an interdisciplinary tumor board, small and superficial BCC can be treated by topical therapy. In cases of a previous BCC history, a prophylactic treatment can be considered. A combination of systemic treatment and neoadjuvant or adjuvant approaches before or after surgery are promising options for a successful outcome, which can further improve the standard treatment for locally advanced BCC. However, due to the lack of therapy success controls for both treatment options, almost all forms of therapy are inferior to micrographically controlled surgery and should therefore only be used if there are substantial reasons against R0 resection. In this review a literature search on PUBMED was carried out and a structured display and analysis of the results are given.

show abstract

Section: Radiotherapymentioning

confidence: 99%

Alternative treatment options for periocular basal cell carcinoma: a narrative review

Erikson¹,

Brosig²,

Zimbelmann³

et al. 2022

Front Oral Maxillofac Med

View full text Add to dashboard Cite

show abstract

“…application using brachytherapy (BRT). EBRT is delivered via photon or electron beams and can be superficial or deeply penetrating, depending on the megavoltage of the different energy sources [8]. RT can be delivered to fields of different sizes and with different complex shapes.…”

Section: When Is Radiotherapy Recommended?mentioning

confidence: 99%

Radiotherapy in the Adjuvant and Advanced Setting of CSCC

Muto

Pastore

2021

Dermatol Pract Concept

View full text Add to dashboard Cite

Introduction: The use of radiotherapy for cutaneous squamous cell carcinoma (CSCC) has solid historical roots. It is used with patients who are not suitable for surgery, patients with high-risk histological features in the adjuvant setting, and in palliative care. Objectives: The aim of this article is to summarize and provide a radiation therapy overview on the indications, effectiveness, and potential adverse events of radiotherapy in the adjuvant and advanced setting of CSCC. Methods: We performed a comprehensive literature review on PubMed, adopted as our biomedical literature database. Articles were selected based on their date of publication (in the last 30 years) and relevance. Results: Radiotherapy (RT) can safely be used to manage non-surgical patients and high-risk patients in the advanced CSCC setting. The remarkable progress of delivery techniques has greatly improved the effectiveness and toxicity profile of RT treatments. From 2D techniques to intensity modulated radiation therapy (IMRT), and brachytherapy, all RT techniques have greatly advanced. To improve acute and chronic side effects, deeper care has been used. As regards CSCC, several dose fractionations and schedules have been suggested, in line with the patient’s age and medical conditions. Conclusions: RT is a fundamental and constantly evolving therapeutic option in the treatment of CSCC, to minimize the risk of recurrence and metastases in the adjuvant setting and in the exclusive treatment for non-surgical patients. Patients’ selection is crucial, together with and a collaborative team working approach among the specialists involved in disease management in the perspective of the best multidisciplinary assessment.

show abstract

“…Wenn eine Operation nicht gewünscht ist, eine inkomplette Resektion erfolgte oder ein lokales Rezidiv vorhanden ist, ist eine Strahlentherapie des BCC in 84-96 % der Fälle kurativ [10].…”

Section: Therapie Und Prognoseunclassified

Aktuelle Therapiekonzepte bei oberflächlichen malignen Tumoren

Scholz

Eckstein²,

Dekowski³

et al. 2019

Laryngo-Rhino-Otol

View full text Add to dashboard Cite

ZusammenfassungIn dieser Übersichtsarbeit werden die diagnostischen und therapeutischen Möglichkeiten bei den häufigsten malignen oberflächlichen Tumoren abgehandelt, hierzu gehören Basalzellkarzinome, konjunktivale Lymphome, Plattenepithelkarzinome und maligne Melanome und deren Vorstufen. Entscheidend für die richtige Diagnostik und Therapie ist eine ausführliche Anamnese, Spaltlampenuntersuchung und Fotodokumentation des Tumorbefunds. Aber auch regelmäßige Kontrollen nach erfolgter Therapie sind unabdingbar.Das Basalzellkarzinom ist der häufigste Tumor der periokulären Haut. Histologisch werden 3 Subtypen (nodulär, superfiziell, Morpheatyp) unterschieden. Eine vollständige Exzision mit entsprechendem Sicherheitsabstand ist immer anzustreben.Das Lymphom ist der häufigste maligne primäre Tumor der Augenhöhle und der okulären Adnexe. Es kann sowohl primär als auch sekundär, im Rahmen einer lymphatischen Systemerkrankung, als auch ein- oder beidseitig auftreten. Das MALT-Lymphom (MALT: Mucosa associated lymphoid tissue) betrifft am häufigsten die Konjunktiven mit 20–33 %. Therapeutisch wird standardmäßig eine perkutane Bestrahlung des Tumors angewandt.Die Plattenepithelkarzinome der Bindehaut und deren Vorstufen (CIN I-III) stellen ebenfalls eine der häufigsten Tumorentitäten am Auge dar. Eine vollständige Tumorexzision ist immer anzustreben, jedoch aufgrund der häufig großflächigen Ausbreitung nicht möglich. Für eine gute Tumorkontrolle sind nach R1-Resektion daher adjuvante Therapien mit Mitomycin C (MMC) oder eine Radiotherapie mit Rutheniumapplikator oder Protonenbestrahlung notwendig.Das Bindehautmelanom ist selten, es kann jedoch lebensbedrohlich sein. Die primär erworbene Melanose (PEM) mit Atypien (PEM I-III) hat je nach Schweregrad ein erhöhtes Entartungsrisiko, dies macht eine Therapie mit Mitomycin-C-Augentropfen notwendig. Bei Verdacht auf einen malignen Prozess ist immer eine Exzision mittels Non-Touch-Technik anzustreben, damit das Streuungsrisiko von Tumorzellen gering bleibt. Zusätzlich ist, abhängig von Lokalisation und Ausbreitung eines Melanoms, immer eine adjuvante Therapie mittels Rutheniumapplikator oder Protonentherapie notwendig.

show abstract

Radiotherapy for management of basal and squamous cell carcinoma

Cited by 12 publications

References 77 publications

Alternative treatment options for periocular basal cell carcinoma: a narrative review

Alternative treatment options for periocular basal cell carcinoma: a narrative review

Radiotherapy in the Adjuvant and Advanced Setting of CSCC

Aktuelle Therapiekonzepte bei oberflächlichen malignen Tumoren

Contact Info

Product

Resources

About